Neoadjuvant Immunotherapy Superior to Targeted Therapy in Stage III Melanoma09/15/2024 majac Alternative Medicine … alternative treatment approach. Broken down by treatment group, the 3-year RFS was: 93% to 95% for patients with an MPR on ICI vs 79% for a …Share on FacebookTweetFollow usSave